Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
GSK pens $1B deal for metabolic oligonucleotide from SiranBio
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides.
James Waldron
May 6, 2026 8:04am
Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal
May 5, 2026 10:40am
Ligand tries to disembark from Viking pact, alleging breach
May 1, 2026 8:31am
BMS calls time on Zymeworks collab, ending work on bispecific
Apr 30, 2026 10:22am
BeOne signs $2B deal for option on preclinical trispecific
Apr 30, 2026 7:55am
AstraZeneca plucks EGFR degrader from Pinetree for $25M
Apr 30, 2026 2:29am
